Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -88.26 Million EUR | 49.31% |
| 2022 | -267.52 Million EUR | -61.55% |
| 2021 | -165.59 Million EUR | 7.3% |
| 2020 | -178.63 Million EUR | -148.24% |
| 2019 | 370.29 Million EUR | 926.42% |
| 2018 | -44.8 Million EUR | 50.1% |
| 2017 | -89.8 Million EUR | -681.5% |
| 2016 | -11.49 Million EUR | 87.15% |
| 2015 | -89.44 Million EUR | -144.22% |
| 2014 | -36.62 Million EUR | -232.34% |
| 2013 | -11.02 Million EUR | -66.72% |
| 2012 | -6.61 Million EUR | 79.93% |
| 2011 | -32.93 Million EUR | -3294.47% |
| 2010 | 1.03 Million EUR | -37.78% |
| 2009 | 1.65 Million EUR | 110.89% |
| 2008 | -15.21 Million EUR | 30.33% |
| 2007 | -21.84 Million EUR | -84.98% |
| 2006 | -11.8 Million EUR | -77.55% |
| 2005 | -6.65 Million EUR | -84.31% |
| 2004 | -3.6 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -54.3 Million EUR | -19.53% |
| 2024 Q2 | -45.43 Million EUR | -6.85% |
| 2024 Q1 | -42.51 Million EUR | 38.65% |
| 2023 Q2 | -10.69 Million EUR | -148.66% |
| 2023 FY | -135.6 Million EUR | 49.31% |
| 2023 Q1 | 21.96 Million EUR | 116.59% |
| 2023 Q4 | -69.3 Million EUR | -129.25% |
| 2023 Q3 | -30.23 Million EUR | -182.82% |
| 2022 Q3 | -37.58 Million EUR | 50.77% |
| 2022 Q1 | -21.14 Million EUR | 93.81% |
| 2022 Q2 | -76.33 Million EUR | -261.01% |
| 2022 Q4 | -132.46 Million EUR | -252.48% |
| 2022 FY | -267.52 Million EUR | -61.55% |
| 2021 Q4 | -341.34 Million EUR | -536.51% |
| 2021 FY | -165.59 Million EUR | 7.3% |
| 2021 Q1 | -50.79 Million EUR | -228.19% |
| 2021 Q2 | -46.75 Million EUR | 7.97% |
| 2021 Q3 | 78.19 Million EUR | 267.27% |
| 2020 Q4 | -15.47 Million EUR | 52.16% |
| 2020 FY | -178.63 Million EUR | -148.24% |
| 2020 Q3 | -32.35 Million EUR | 62.47% |
| 2020 Q2 | -86.21 Million EUR | -93.37% |
| 2020 Q1 | -44.58 Million EUR | -96.16% |
| 2019 Q2 | -44.36 Million EUR | 16.67% |
| 2019 FY | 370.29 Million EUR | 926.42% |
| 2019 Q4 | -22.72 Million EUR | -104.63% |
| 2019 Q1 | -53.24 Million EUR | -711.41% |
| 2019 Q3 | 490.63 Million EUR | 1205.85% |
| 2018 FY | -44.8 Million EUR | 50.1% |
| 2018 Q2 | -33.75 Million EUR | -5.35% |
| 2018 Q3 | 12.27 Million EUR | 136.36% |
| 2018 Q1 | -32.03 Million EUR | -17.56% |
| 2018 Q4 | 8.7 Million EUR | -29.04% |
| 2017 Q3 | -29.65 Million EUR | -36.79% |
| 2017 FY | -89.8 Million EUR | -681.5% |
| 2017 Q2 | -21.67 Million EUR | -93.1% |
| 2017 Q1 | -11.22 Million EUR | -130.35% |
| 2017 Q4 | -27.25 Million EUR | 8.1% |
| 2016 Q4 | 36.99 Million EUR | 253.28% |
| 2016 Q2 | -6.95 Million EUR | 60.02% |
| 2016 FY | -11.49 Million EUR | 87.15% |
| 2016 Q1 | -17.39 Million EUR | 33.58% |
| 2016 Q3 | -24.13 Million EUR | -247.04% |
| 2015 Q4 | -26.19 Million EUR | 5.35% |
| 2015 Q1 | -15.33 Million EUR | -43.37% |
| 2015 FY | -89.44 Million EUR | -144.22% |
| 2015 Q3 | -27.67 Million EUR | -36.63% |
| 2015 Q2 | -20.25 Million EUR | -32.1% |
| 2014 Q1 | -7.57 Million EUR | -43.84% |
| 2014 FY | -36.62 Million EUR | -232.34% |
| 2014 Q4 | -10.69 Million EUR | -1.8% |
| 2014 Q3 | -10.5 Million EUR | -38.68% |
| 2014 Q2 | -7.57 Million EUR | 0.0% |
| 2013 Q3 | -5.26 Million EUR | -72.85% |
| 2013 Q4 | -5.26 Million EUR | 0.0% |
| 2013 Q2 | -3.04 Million EUR | 0.0% |
| 2013 Q1 | -3.04 Million EUR | -32.05% |
| 2013 FY | -11.02 Million EUR | -66.72% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | -2.3 Million EUR | -163.84% |
| 2012 FY | -6.61 Million EUR | 79.93% |
| 2012 Q3 | 3.61 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | -32.93 Million EUR | -3294.47% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | 1.03 Million EUR | -37.78% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 1.65 Million EUR | 110.89% |
| 2008 FY | -15.21 Million EUR | 30.33% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | -21.84 Million EUR | -84.98% |
| 2006 FY | -11.8 Million EUR | -77.55% |
| 2005 FY | -6.65 Million EUR | -84.31% |
| 2004 FY | -3.6 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -2486.841% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 30.707% |
| Adocia SA | -17.62 Million EUR | -400.868% |
| Aelis Farma SA | -6.46 Million EUR | -1266.089% |
| Biophytis S.A. | -14.33 Million EUR | -515.803% |
| Advicenne S.A. | -6.45 Million EUR | -1266.935% |
| genOway Société anonyme | 2.06 Million EUR | 4373.625% |
| IntegraGen SA | -183.77 Thousand EUR | -47929.058% |
| Medesis Pharma S.A. | -4.22 Million EUR | -1986.921% |
| Neovacs S.A. | -6.9 Million EUR | -1177.776% |
| NFL Biosciences SA | -4.43 Million EUR | -1892.204% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -11241.404% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -2713.384% |
| Sensorion SA | -22.31 Million EUR | -295.61% |
| Theranexus Société Anonyme | -7.64 Million EUR | -1054.719% |
| TME Pharma N.V. | -5.62 Million EUR | -1469.399% |
| Valbiotis SA | -7.16 Million EUR | -1132.723% |
| TheraVet SA | -2.17 Million EUR | -3957.866% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -335.05% |
| argenx SE | -417.15 Million EUR | 78.842% |
| BioSenic S.A. | -7.04 Million EUR | -1153.736% |
| Celyad Oncology SA | -8.45 Million EUR | -943.668% |
| DBV Technologies S.A. | -85.24 Million EUR | -3.539% |
| Genfit S.A. | -26.58 Million EUR | -232.065% |
| GeNeuro SA | -14.35 Million EUR | -514.76% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -451.885% |
| Innate Pharma S.A. | -12.66 Million EUR | -596.685% |
| Inventiva S.A. | -102.7 Million EUR | 14.065% |
| MaaT Pharma SA | -19.94 Million EUR | -342.576% |
| MedinCell S.A. | -20.97 Million EUR | -320.761% |
| Nanobiotix S.A. | -26.77 Million EUR | -229.598% |
| Onward Medical N.V. | -35.46 Million EUR | -148.888% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -1840.19% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -283.986% |
| Oxurion NV | -12.11 Million EUR | -628.844% |
| Pharming Group N.V. | -4.87 Million EUR | -1708.837% |
| Poxel S.A. | -28.76 Million EUR | -206.852% |
| GenSight Biologics S.A. | -29.69 Million EUR | -197.222% |
| Transgene SA | -30.01 Million EUR | -194.092% |
| Financière de Tubize SA | -2.14 Million EUR | -4016.794% |
| UCB SA | 604 Million EUR | 114.613% |
| Valneva SE | -82.08 Million EUR | -7.524% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -206.076% |